by ASTCT Advocacy Update
The U.S. Food and Drug Administration (FDA) has announced that Risk Evaluation and Mitigation Strategies (REMS) will no longer be required for BCMA- and CD19-directed autologous CAR T cell...
by ASTCT Talks
In the next installment of ASTCT's Titans of Transplant series, Dr. Shernan Holtan sits down with Dr. Daniel Weisdorf—renowned leader, mentor and pioneer in cellular therapy and...
by Jayne Kramer
A new blog post from Jayne Kramer spotlights ASTCT’s upgraded Practice Guidelines mobile app — now featuring a modern interface, enhanced diagnostic tools and improved navigation.
by David Porter, MD
In this month's President’s Message, Dr. David Porter shares his perspective on the recent dismissal of the CDC’s vaccine advisory committee—and why it matters.
by Alex Kadhim
Researchers from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) conducted the PHYLOS trial and found that posttransplant cyclophosphamide (PTCy)-based prophylaxis significantly reduces the...
by ASTCT Talks
An expert panel highlights key presentations in multiplemyeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.
CancerNetwork®, in collaboration with The...